Wells Fargo becomes bullish on this biotech company
Health care industry,Neurocrine Biosciences Inc,Wells Fargo & Co,Stock markets,Markets,Business,Wall Street,Breaking News: Investing,business news
#Wells #Fargo #bullish #biotech #company
Neurocrine Biosciences ‘ drug pipeline is turning a corner and the company will be “knocking on the doors of the large-cap club” soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday’s close. Bansal forecasts the company’s congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. “Crinecerfont alone is enough to make for a buy case,” Bansal wrote in a Tuesday note. “We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity.” Elsewhere in the company’s pipeline, Neurocrine’s depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open “a whole new chapter” of a $1.2 billion peak sales opoprtunity. The NBI-‘845 treatment could be “another blockbuster opportunity,” Bansal said, citing the treatment’s once daily administration as a factor in his assessment. Competing therapies are taken twice a day, he said. Shares are up nearly 6% in 2024. The stock has rallied about 35% over the last 12 months. —CNBC’s Michael Bloom contributed to this report.
Health care industry,Neurocrine Biosciences Inc,Wells Fargo & Co,Stock markets,Markets,Business,Wall Street,Breaking News: Investing,business news
#Wells #Fargo #bullish #biotech #company
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.